We invite you to the Autolus AUCATZYL (obecabtagene autoleucel) meeting, Rethinking CAR T for adult r/r B-ALL,
taking place on Tuesday, 10 February at Searcys, 30 Euston Square, London, NW1 2FB.
If you are unable to attend in person, a virtual attendance option is available.
Agenda
18.30 Registration and reception
19.00 Program and Q&A
20.30 Networking
Our Esteemed Faculty
Dr Anna Castleton
Program Chair
Consultant Haematologist
The Christie NHS Foundation Trust
Dr Martin Pule
Founder and
Chief Scientific Officer
Autolus Therapeutics
Dr Claire Roddie
Associate Professor in Haemato – Oncology University College London Cancer Institute
Dr Eleni Tholouli
Consultant Haematologist
Manchester University – NHS Foundation Trust
Dr Michelle Lannon
Consultant Haematologist
The Newcastle Upon Tyne Hospitals NHS Foundation Trust
AUCATZYL is indicated for the treatment of adult patients (≥18 years) with relapsed or refractory B cell precursor acute lymphoblastic leukaemia.
▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked
to report any suspected adverse reactions.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Autolus Therapeutics at MedInfo.europe@autolus.com or call 0800 0318 140